J. Yang

发表

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.

M. Ahn, Y. Ohe, H. Saka, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.

T. Mok, Yi-long Wu, S. Thongprasert, 2017, Lung cancer.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation‐positive advanced non‐small cell lung cancer (aNSCLC): 134O_PR

P. Jänne, T. Mitsudomi, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

T. Mok, Y. Ichinose, M. Maemondo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

T. Mitsudomi, S. Peters, D. Planchard, 2019, Annals of Oncology.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

K. O'Byrne, T. Mok, E. Tan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.

S. Peters, S. Senan, D. Tan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

T. Mitsudomi, S. Peters, D. Planchard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study.

J. Barrett, M. Ahn, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1263PAFATINIB (A) FOLLOWED BY A + PACLITAXEL (P) OR INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC) IN PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG: SUBGROUP ANALYSIS OF LUX-LUNG 5 (LL5).

J. Strausz, F. de Marinis, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5).

F. de Marinis, D. Planchard, M. Schuler, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

449PDUPDATED SAFETY AND EFFICACY FROM A PHASE I STUDY OF AZD9291 IN PATIENTS (PTS) WITH EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC).

M. Ranson, E. Felip, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Overview of current systemic management of EGFR-mutant NSCLC

Jie Yang, T. Mok, H. Loong, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Y Huang, L. Sequist, K. O'Byrne, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

P. Jänne, P. Ascierto, P. V. Van Schil, 2020, Annals of Oncology.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

T. Mok, Y. Ichinose, M. Maemondo, 2017 .

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

E. Felip, S. Choo, E. Garralda, 2023, ESMO open.

Osimertinib (AZD9291) in pre‐treated pts with T790M‐positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results: LBA2_PR

P. Jänne, T. Mitsudomi, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reply to the letter to the editor 'What is the clinical impact of the LUX-Lung 5 trial?' by Addeo.

D. Planchard, M. Schuler, J. Yang, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Osimertinib as first‐line treatment for EGFR mutation‐positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts: LBA1_PR

P. Jänne, Y. Ohe, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation‐positive non‐small cell lung cancer (NSCLC): Post‐hoc analyses of LUX‐Lung 3 (LL3) and LUX‐Lung 6 (LL6): 138PD

L. Sequist, K. O'Byrne, T. Mok, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI

T. Mitsudomi, T. Mok, F. Andersohn, 2016 .

456PPRECLINICAL EVIDENCE AND CLINICAL CASES OF AZD9291 ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM).

P. Janne, D. Cross, P. Ballard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial.

S. Gettinger, M. Ahn, D. Camidge, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.